drugset / Trial / NCT00321633

Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer

NCT00321633 ↗

Phase 2 Completed 148 enrolled University College London Hospitals
RandomizedOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as carboplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether carboplatin is more effective than docetaxel in treating patients with metastatic genetic breast cancer. PURPOSE: This randomized phase II trial is studying carboplatin to see how well it works compared to docetaxel in treating women with metastatic genetic breast cancer.

Timeline

Start
2005-09
Primary completion
2009-09
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule — Intravenous
Subject Docetaxel Small molecule — Intravenous